natgillin/translations-raw huggingface dataset:
• If the Provenge bag leaks, is damaged, or if particles or clumps remain in the bag after gentle manual mixing, the product must not be used.
• Če vrečka z zdravilom Provenge pušča, je poškodovana ali v njej po nežnem ročnem mešanju ostanejo delci ali grudice, zdravila ne smete uporabiti.
Provenge should be delayed in patients with active systemic infection until resolution.
Uporabo zdravila Provenge je treba pri bolnikih z aktivno sistemsko okužbo prestaviti, dokler okužba ne izzveni.
You will be monitored before and during the infusion.
Med infundiranjem in po njem vas bodo nadzirali.
No Grade 4 or 5 acute infusion reactions were reported in patients in the Provenge group.
O reakcijah na infundiranje 4. ali 5. stopnje pri bolnikih v skupini z zdravilom Provenge niso poročali.
• Provenge is shipped directly to the medical facility where the infusion will be administered.
• Zdravilo Provenge se pošlje neposredno zdravstveni ustanovi, kjer bo bolnik prejel infuzijo.
Intermediate results were observed in patients with baseline PSA > 22.1 to 50.1 ng/mL [HR=0.685 (95% CI: 0.431, 1.088)] and patients with baseline PSA > 50.1 to 134.1 ng/mL [HR=0.819 (95% CI: 0.532, 1.262)].
Vmesne rezultate so upoštevali pri bolnikih z izhodiščnim PSA > 22,1 do 50,1 ng/ml [RT = 0,685 (95-% IZ: 0,431; 1,088)] in pri bolnikih z izhodiščnim PSA > 50,1 do 134,1 ng/ml [RT = 0,819 (95-% IZ: 0,532; 1,262)].
Neither endpoint met statistical significance.
Noben opazovani dogodek ni bil statistično značilen.
In the event of an acute infusion reaction, the infusion rate may be decreased, or the infusion stopped, depending on the severity of the reaction.
V primeru akutne reakcije na infundiranje se lahko hitrost infundiranja zmanjša ali infundiranje ustavi, odvisno od resnosti reakcije.
Provenge can only be administered by a doctor or nurse who has been trained in using this medicine.
Zdravilo Provenge vam lahko da samo zdravnik ali medicinska sestra, ki sta se usposobila za dajanje tega zdravila.
Control (N=45)
Kontrola (N = 45)
Serious adverse reactions include acute infusion reactions, catheter sepsis, staphylococcal bacteraemia, myocardial infarction, and cerebrovascular events.
Resni neželeni učinki vključujejo akutne reakcije na infundiranje, sepso zaradi katetra, stafilokokno bakteriemijo, miokardni infarkt, in cerebrovaskularne dogodke.
Common side effects (may affect up to 1 in 10 patients):
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov):
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INSULATED POLYURETHANE CONTAINER
PODATKI NA ZUNANJI OVOJNINI IZOLIRANI POLIURETANSKI VSEBNIK
Dendreon UK Ltd. 41 Chalton Street London, NW1 1JD United Kingdom
Dendreon UK Ltd. 41 Chalton Street London, NW1 1JD Velika Britanija
Patient leukapheresis material is tested for transmissible infectious agents in line with applicable local requirements.
Bolnikov levkaferezni material je testiran za povzročitelje nalezljivih bolezni v skladu z veljavnimi lokalnimi zahtevami.
Dendreon UK Limited 41 Chalton Street London, NW1 1JD United Kingdom
Dendreon UK Limited 41 Chalton Street London, NW1 1JD Velika Britanija
A smaller treatment effect was observed in those with baseline PSA > 134.1 ng/mL [HR=0.853 (95% CI: 0.554, 1.315)].
Manjši učinek zdravljenja so opazili pri tistih z izhodiščnim PSA > 134,1 ng/ml [RT = 0,853 (95-% IZ: 0,554; 1,315)].
Control (N=171)
Kontrola (N = 171)
PSA doubling time, the number of patients who develop metastatic disease, subsequent therapies received after diagnosis of metastatic disease, and efficacy parameters following subsequent therapies, including PSA progression, PSA progression-free survival, time to next line therapy, and overall survival.
izhodišču, vključno s PSA in časom podvojitve PSA, številom bolnikov, ki razvijejo metastatsko bolezen, nadaljnjimi terapijami, ki so jih bolniki dobili po diagnozi metastatske bolezni, ter parametri učinkovitosti po nadaljnjih terapijah, med drugim nadaljnji razvoj PSA, preživetje brez napredovanja
There is no relevant use of Provenge in the paediatric population in children and adolescents less than 18 years of age in the indication of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.
Pediatrična populacija Zdravilo Provenge ni primerno za uporabo pri pediatrični populaciji pri otrocih in mladostnikih, starih manj kot 18 let, za indikacijo asimptomatskega ali minimalno simptomatskega metastatskega (nevisceralnega), na kastracijo odpornega raka prostate pri odraslih moških, pri katerih kemoterapija še ni klinično indicirana.
Acute infusion reactions
Akutne reakcije na infundiranje
In controlled clinical trials, 25.4% of patients treated with Provenge required more than 3 leukapheresis procedures in order to receive 3 infusions.
V kontroliranih kliničnih preskušanjih so bili pri 25,4 % bolnikov, zdravljenih z zdravilom Provenge, potrebni več kot 3 postopki levkafereze za prejem 3 infuzije.
Control (N=33)
Kontrola (N = 33)
Adverse reactions associated with leukapheresis
Neželeni učinki, povezani z levkaferezo
• Once the patient is prepared for infusion and the APPROVED Final Product Disposition Notification form has been received, the Provenge bag should be removed from the insulated container and inspected for leaks, external damage, foreign particulate matter, or clumps/clots.
• Ko je bolnik pripravljen na infundiranje in po prejemu ODOBRENEGA obvestilom o končnem razpolaganju z zdravilom, se vrečko z zdravilom Provenge odstrani iz izoliranega vsebnika in pregleda, ali pušča, ima vidne poškodbe, tujke, grudice ali strdke.
Before, or on the day, your blood cells are collected, a blood sample will be taken from you for a complete blood count (CBC) test.
Testi Pred dnevom odvzema krvnih celic ali na dan odvzema vam bodo odvzeli vzorec krvi, da opravijo preiskavo celotne krvne slike.
Product characterization shows that PAP and PAP-GM-CSF fusion protein-specific T cells are generated during treatment and are detected in the peripheral blood of patients after treatment with Provenge.
Karakterizacija zdravila kaže, da med zdravljenjem nastajajo T-celice PAP in PAP-GM-CSF, specifične za fuzijski protein, ki so po zdravljenju z zdravilom Provenge zaznavne v periferni krvi bolnikov.
Prior to infusion, it must be confirmed that the patient's identity matches the essential unique patient information on the Provenge bag and on the Final Product Disposition Notification form (see sections 4.2 and 6.6).
Pred infundiranjem je treba potrditi, da se identiteta bolnika ujema z bistveno edinstveno informacijo o bolniku na infuzijski vrečki z zdravilom Provenge in na obvestilu o končnem razpolaganju z zdravilom (glejte poglavji 4.2 in 6.6).
To minimize potential acute infusion reactions such as chills and/or fever, it is recommended that patients be pre-medicated orally with paracetamol and an antihistamine approximately 30 minutes prior to administration of Provenge.
Za zmanjšanje možne akutne reakcije na infundiranje, kot sta mrzlica in/ali zvišana telesna temperatura, se priporoča, da se bolnike približno 30 minut pred uporabo zdravila Provenge peroralno premedicira s paracetamolom in antihistaminikom.
If you have any further questions, ask your doctor or nurse.
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali medicinsko sestro.
Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (nonvisceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.
Zdravilo Provenge je indicirano za zdravljenje asimptomatskega ali minimalno simptomatskega metastatskega (nevisceralnega), na kastracijo odpornega raka prostate pri odraslih moških, pri katerih kemoterapija še ni klinično indicirana.
To reduce these reactions your doctor may suggest that you take paracetamol and an antihistamine medicine about 30 minutes before your treatment with Provenge.
Za zmanjšanje teh reakcij lahko zdravnik predlaga, da približno 30 minut pred zdravljenjem z zdravilom Provenge vzamete paracetamol in antihistaminik.
Rash
Roki
In controlled clinical trials, cerebrovascular events (hemorrhagic and ischaemic strokes) were observed in 3.5% of patients in the Provenge group compared with 2.6% of patients in the control group.
V kontroliranih kliničnih preskušanjih so opazili cerebrovaskularne dogodke (hemoragična in ishemična kap) pri 3,5 % bolnikov v skupini z zdravilom Provenge v primerjavi z 2,6 % bolnikov v kontrolni skupini.
Other side effects with Provenge include:
Drugi neželeni učinki zdravila Provenge vključujejo:
• Infusion must begin prior to the expiration date and time indicated on the Final Product Disposition Notification form and bag label.
• Infuzija se mora začeti pred datumom in časom poteka roka uporabnosti, navedenega na obvestilu o končnem razpolaganju z zdravilom in nalepki vrečke.
Prior to the first leukapheresis proceedure, a complete blood count (CBC) test should be performed.
Pred prvim postopkom levkafereze je treba opraviti preiskavo celotne krvne slike.
Disposal Any unused product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
What Provenge looks like and contents of the pack Provenge is a slightly cloudy dispersion of cream-to-pink colour and is supplied in a plastic bag with 3 sample ports.
Izgled zdravila Provenge in vsebina pakiranja Zdravilo Provenge je rahlo motna disperzija kremne do rožnate barve, dobavljena v plastični vrečki s
Provenge has moderate influence on the ability to drive and use machines, as it may cause fatigue, dizziness, syncope, chills, and headache.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Provenge ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji, saj lahko povzroči utrujenost, omotico, sinkopo, mrzlico in glavobol.
To conduct study P12-1 to evaluate characteristics predictive of a positive imaging study for distant metastases in patients with castrate-resistant prostate cancer.
Da izvede študijo P12-1, s katero se vrednoti zmožnost za napoved pozitivnega rezultata pri preslikovanju razsejanih metastaz pri bolnikih z na kastracijo odpornim rakom prostate.
If your infusion of Provenge has to be interrupted for any reason, your doctor will not be able to restart the infusion if the medicine has been at room temperature for more than 3 hours.
Če je treba infundiranje zdravila Provenge zaradi katerega koli razloga prekiniti, vaš zdravnik z infundiranjem ne bo mogel nadaljevati, če je bilo zdravilo več kot 3 ure pri sobni temperaturi.
However, as Provenge is an autologous product, a positive test does not preclude the manufacture of the product.
Vendar pa je zdravilo Provenge avtologno zdravilo, zato pozitivni test ne prepreči izdelave zdravila.
Study D9901 was a randomised, double-blind, controlled, multicentre trial in patients with metastatic castrate resistant prostate cancer and no cancer-related pain.
Podporne študije Študija D9901 je bilo randomizirano, dvojno slepo, kontrolirano, multicentrično preskušanje pri bolnikih z metastatskim, na kastracijo odpornim rakom prostate brez bolečin, povezanih z rakom.
Patients with renal impairment and/or hyperkalaemia The content of sodium and potassium per infusion should be taken into account if administered in patients with cardiovascular diseases and/or renal impairment.
Bolniki z okvaro ledvic in/ali hiperkaliemijoVsebnost natrija in kalija na infuzijo je treba upoštevati pri dajanju zdravila bolnikom s kardiovaskularno boleznijo in/ali ledvično okvaro.
If you miss an appointment and you cannot be given your Provenge infusion, it will no longer be usable.
Če se termina ne boste držali in tako infuzije zdravila Provenge ne boste mogli prejeti, bo zdravilo postalo neuporabno.
Do not initiate infusion if expired, after 3 hours at room temperature (25°C), or if particles/clumps are visible despite gentle manual mixing.
Če je potekel rok uporabnosti, po 3 urah pri sobni temperaturi (25°C) ali če so kljub nežnemu ročnemu mešanju prisotni delci/grudice, zdravila ne infundirajte.
During or within 24 hours of the infusion, you may develop very common symptoms such as chills, fever, tiredness, feeling weak, headache, feeling sick (nausea), being sick (vomiting), muscle ache, and dizziness,.
Med infundiranjem ali v 24 urah po njem se bodo morda pojavili zelo pogosti simptomi, na primer mrzlica, zvišana telesna temperatura, utrujenost, občutek šibkosti, glavobol, občutek slabosti (navzea),
Submission of study protocol within 1 month of authorisation
Protokol študije predložiti najkasneje 1 mesec po izdaji dovoljenja za promet z zdravilomletno obveščanje o napredovanju študije
Your doctor will give you a schedule for your cell collection and infusion appointments.
Vaš zdravnik vam bo izročil načrt za odvzem celic in obisk zaradi infundiranja.
When given as a drip (infusion) into your vein, Provenge works by teaching your immune cells to recognise and attack prostate cancer cells.
Provenge deluje tako, da nauči vaše imunske celice, da prepoznavajo in napadajo celice raka prostate.
The IMPACT study was a randomised, double-blind, controlled, multicentre trial in patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
Študija IMPACT je bilo randomizirano, dvojno slepo, kontrolirano, multicentrično preskušanje pri bolnikih z asimptomatskim ali minimalno simptomatskim metastatskim, na kastracijo odpornim rakom prostate.
Provenge is not tested for transmissible infectious agents.
Zdravilo Provenge ni bilo testirano za povzročitelje nalezljivih bolezni.
Patients with renal impairment and/or hyperkalaemia and/or on a controlled potassium diet Provenge has not been investigated in patients with renal impairment.
Bolniki z okvaro ledvic in/ali hiperkaliemijo in/ali bolniki na dieti z nadziranim vnosom kalija Zdravila Provenge pri bolnikih z okvarjenim delovanjem ledvic niso preučili.
Preparing the infusion Take care to ensure aseptic handling when preparing the infusion.
Pri pripravi infuzije zagotovite aseptično ravnanje.
For full instructions on the preparation and handling of Provenge, see section 6.6.
Za celotna navodila o pripravi zdravila Provenge in rokovanju z njim glejte poglavje 6.6. 4.3 Kontraindikacije
The study should provide a summary of baseline patient characteristics including PSA and
Študija mora vsebovati povzetek glavnih značilnosti pacientov na
Reports of serious infection have been received in post-marketing surveillance including devicerelated infection, device-related sepsis, pneumonia, sepsis, bacteraemia, and urinary tract infection.
Poročila o resnih okužbah, prejeta v obdobju trženja, so vključevala okužbe, povezane s pripomočkom, sepso, povezano s pripomočkom, pljučnico, sepso, bakteriemijo in okužbo sečil.
What Provenge contains
Kaj vsebuje zdravilo Provenge
Patient leukapheresis material is tested for transmissible infectious agents in line with applicable member state requirements.
Material iz bolnikove levkafereze se testira za povzročitelje nalezljivih bolezni v skladu z upoštevanimi zahtevami držav članic.
Additionally, there have been reports of thrombocytopenia received in spontaneous post-marketing reporting that have been temporally associated with leukapheresis.
Iz spontanega poročanja v obdobju trženja zdravila so bila prejeta so tudi poročila o trombocitopeniji, ki so bila začasno povezana z levkaferezo.
Each dose of Provenge is preceded by a standard leukapheresis procedure approximately 3 days prior to the scheduled infusion date.
Vsak odmerek zdravila Provenge sledi standardnemu postopku levkafereze približno 3 dni pred načrtovanim datumom infundiranja.
Provenge is intended solely for autologous use.
Zdravilo Provenge je namenjeno izključno avtologni uporabi.
• approximately 45 mg potassium per infusion.
• približno 45 mg kalija na infuzijo.
Appropriate precautions should be employed when handling Provenge (see section 4.4).
Pri rokovanju z zdravilom Provenge je treba upoštevati ustrezne previdnostne ukrepe (glejte poglavje 4.4).
Acute infusion reactions (reported within 1 day of infusion) included, but were not limited to, fever, chills, respiratory events (dyspnoea, hypoxia, and bronchospasm), nausea, vomiting, fatigue, hypertension, and tachycardia.
Akutne reakcije na infundiranje (o njih so poročali v 1 dnevu od infundiranja) so med drugim vključevale zvišano telesno temperaturo, mrzlico, respiratorne dogodke (dispneja, hipoksija in bronhospazem), navzeo, bruhanje, utrujenost, hipertenzijo in tahikardijo.
In controlled clinical trials, 71.2% of patients in the Provenge group developed an acute infusion reaction.
Akutna reakcija na infundiranje V kontroliranih kliničnih preskušanjih se je pri 71,2 % bolnikov v skupini z zdravilom Provenge razvila akutna reakcija na infundiranje.
• Contents of the bag will be slightly cloudy, with a cream to pink colour.
• Vsebina vrečke je rahlo motna in kremne do rožnate barve.
Each dose of Provenge requires a standard leukapheresis procedure approximately 3 days prior to the infusion.
Za vsak odmerek zdravila Provenge je potreben standardni postopek levkafereze približno 3 dni pred infundiranjem.
Preparing the infusion • Take care to ensure aseptic handling when preparing the infusion.
• Pri pripravi infuzije zagotovite aseptično ravnanje.
• approximately 800 mg sodium per infusion.
• približno 800 mg natrija na infuzijo.
If you need more information on the testing of your blood please ask your doctor or nurse.
Če potrebujete več informacij o krvnih preiskavah, se posvetujte z zdravnikom ali medicinsko sestro.
Posology One dose of Provenge contains a minimum of 50 x 106 autologous CD54+ cells activated with
Odmerjanje En odmerek zdravila Provenge vsebuje najmanj 50 x 106 avtolognih celic CD54+, aktiviranih s
The most commonly reported adverse reactions are chills, fatigue, pyrexia, nausea, arthralgia, headache, and vomiting.
Najpogosteje poročani neželeni učinki so mrzlica, utrujenost, pireksija, navzea, artralgija, glavobol in bruhanje.
Visit 5 - Blood cell collection (leukapheresis)
5. obisk - odvzem krvnih celic (levkafereza)
Dispersion for infusion.
disperzija za infundiranje
EXPIRY DATE
• kap v anamnezi
This medicinal product contains approximately 800 mg sodium per infusion.
To zdravilo vsebuje približno 800 mg natrija na infuzijo.
Visit 3 - Blood cell collection (leukapheresis)
3. obisk - odvzem krvnih celic (levkafereza)
Hyperkalaemia should be corrected prior to Provenge administration (see section 4.2).
Hiperkaliemijo je treba pred začetkom uporabe zdravila Provenge popraviti (glejte poglavje 4.2).
Accordingly, healthcare professionals should employ appropriate precautions when handling leukapheresis material or Provenge.
Zdravstveno osebje mora zato pri rokovanju z levkafereznim materialom ali zdravilom Provenge uporabljati ustrezne previdnostne ukrepe.
• Upon completion of the infusion, the patient specific label on the infusion bag should be removed and adhered to the patient file.
• Po končanem infundiranju je treba nalepko na infuzijski vrečki, specifično za bolnika, odlepiti in nalepiti v bolnikovo kartoteko.
To mitigate such reactions, premedication, consisting of paracetamol and an antihistamine was administered in clinical studies prior to infusion.
Za lajšanje teh reakcij so v kliničnih študijah pred infundiranjem bolniki prejeli premedikacijo, ki je vsebovala paracetamol in antihistaminik.
Patients with positive serology tests for human immunodeficiency virus [HIV] 1 and 2, human T cell lymphotropic virus [HTLV] 1, and hepatitis B and C were excluded from controlled clinical trials.
celični limfotropni virus [HTLV]-1 in virus hepatitisa B in C so bili iz kontroliranih kliničnih preskušanj izločeni.
Embolic and thrombotic events Provenge should be used with caution in patients with a history of embolic and thrombotic disorders.
Embolični in trombotični dogodki Pri bolnikih z emboličnimi in trombotičnimi dogodki v anamnezi je treba zdravilo Provenge uporabljati previdno.
Therefore patient leukapheresis material and Provenge may carry the risk of transmitting infectious diseases to healthcare professionals handling the product.
Material iz bolnikove levkafereze zato lahko predstavlja tveganje, da se zdravstveno osebje, ki z njim rokuje, naleze kužnih bolezni.
Pregnancy Provenge is not intended for use in women.
Zdravilo Provenge ni namenjeno ženskam.
- decrease of platelets in the blood due to the leukapheresis procedure Uncommon side effects (may affect up to 1 in 100 patients - severe infection in the blood from a contaminated catheter (catheter sepsis) - infection from a contaminated catheter (catheter-related infection) - skin infection of the area where the infusion drip was inserted
- huda okužba krvi (sepsa) - huda okužba krvi zaradi kontaminacije katetra (sepsa zaradi katetra) - okužba zaradi kontaminacije katetra (okužba zaradi katetra) - okužba predela kože, kjer je vstavljena infuzija
In controlled clinical trials, 23.8% of patients treated with Provenge required opioids (a single dose of pethidine) on the day of infusion for infusion reactions (see sections 4.2 and 4.8).
V kontroliranih kliničnih preskušanjih so bili pri 23,8 % bolnikov, zdravljenih z zdravilom Provenge, potrebni opioidi (enojni odmerek pethidina) na dan infundiranja zaradi reakcije na infuzijo (glejte poglavji 4.2 in 4.8).
Additional CBC tests may be performed in accordance with local requirements.
Dodatne preiskave celotne krvne slike se opravijo v skladu z lokalnimi zahtevami.
Fertility Effect on male fertility is not known.
Učinek na sposobnost razmnoževanja pri moških ni znan.
Handling precautions for control of infectious disease Provenge is prepared from human blood of the specific patient and is not tested for transmissible infectious agents.
Zdravilo Provenge se pripravlja iz človeške krvi specifičnega bolnika in se na povzročitelje nalezljivih bolezni ne testira.
Accordingly, healthcare professionals should employ appropriate precautions when handling leukapheresis material or Provenge (see section 4.4).
Zato mora zdravstveno osebje, ko rokuje z materialom levkafereze ali zdravilom Provenge (glejte poglavje 4.4), uporabljati ustrezne previdnostne ukrepe.
• Specific handling and administration requirements for Provenge
• Posebne zahteve glede ravnanja z zdravilom Provenge in njegovo uporabo
Reactions included chills, fever, fatigue, asthenia, dyspnoea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting.
Reakcije so vključevale mrzlico, zvišano telesno temperaturo, utrujenost, astenijo, dispnejo, hipoksijo, bronhospazem, omotico, glavobol, hipertenzijo,
If not used immediately, in-use storage times and conditions should not exceed 3 hours at room temperature (25°C).
Čas shranjevanja zdravila, ki se ne uporabi takoj, ne sme biti daljši kot 3 ure pri sobni temperaturi (25°C).
Steps before Provenge treatment
Koraki pred zdravljenjem z zdravilom Provenge 1.
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency of occurrence: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
V nadaljevanju je seznam neželenih učinkov na podlagi izkušenj iz kliničnih preskušanj in obdobja trženja zdravila, razvrščen po organskih sistemih in pogostnosti pojava: zelo pogosti (≥1/10), pogosti
In post-marketing experience of greater than 5,000 patients treated, this incidence is approximately 19% (see section 4.4).
V izkušnjah iz obdobja trženja z več kot 5.000 zdravljenimi bolniki je bila ta incidenca približno 19 %
BATCH NUMBER, DONATION AND PRODUCT CODES Lot /COI {lot number/chain of identity} First Name, Middle Initial, Last Name {patient name} DOB {patient date of birth}
ŠTEVILKA SERIJE, ENOTNE OZNAKE DAROVANJA IN IZDELKOV Serija/COI {številka serije/neprekinjena veriga identitete} Ime, priimek {bolnikovo ime}
Gently mix and re-suspend the contents of the bag, inspecting for particles, clumps or clots.
Vsebino vrečke nežno premešajte in ponovno suspendirajte ter preverite, ali vsebuje delce, grudice ali strdke.
Cerebral infarction
Možganska kap